TVTX: Guggenheim Raises PT
Guggenheim analyst Vamil Divan raises price target on Travere Therapeutics to $65 and keeps Buy rating ahead of Q2 earnings
TVTX Guggenheim analyst Vamil Divan raised the firm's price target on Travere Therapeutics to $65 from $56 and keeps a Buy rating on the shares, which remain the analyst's "Best Idea." The firm is updating its Travere model ahead of Q2 earnings expected in early August, noting that the report will give the "first concrete insights" on how the Filspari launch in focal segmental glomerulosclerosis is proceeding after the FDA approval on April 13.